Gartisertib is a pyrazolopyrimidine compound with substituents at positions 2, 3, and 6: amino, N-[5-fluoro-4-(4-{[4-(oxetan-3-yl)piperazin-1-yl]carbonyl}piperidin-1-yl)pyridin-3-yl]aminoacyl, and fluoro groups, respectively. It is an inhibitor of ATR kinase and exhibits antineoplastic activity. It functions as an antineoplastic agent, an inhibitor of EC 2.7.11.1 (non-specific serine/threonine protein kinase), and EC 2.7.1.137 (phosphatidylinositol 3-kinase). It is also a pyridine, piperidinecarboxamide, oxetane, N-acylpiperazine, aromatic amine, secondary carboxamide, and primary amino compound.
